Andra AP fonden Boosts Stake in Edwards Lifesciences Corporation $EW

Key Points

• Andra AP fonden increased its Edwards Lifesciences stake by 49% in the second quarter, adding 56,300 shares to hold 171,269 shares valued at approximately $15.5 million. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences reported quarterly earnings of $0.78 per share, exceeding estimates by $0.04, while revenue rose 13.6% year over year to $1.74 billion. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77 and full-year guidance of $2.95–$3.05.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $100.27 versus the stock’s reported price of $88.81. Recent insider activity was negative, with executives selling shares during the quarter.

Andra AP fonden boosted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 49.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 171,269 shares of the medical research company's stock after purchasing an additional 56,300 shares during the period. Andra AP fonden's holdings in Edwards Lifesciences were worth $15,493,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rehmann Capital Advisory Group lifted its holdings in shares of Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after purchasing an additional 130 shares during the period. NorthRock Partners LLC grew its position in Edwards Lifesciences by 1.0% in the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company's stock valued at $1,465,000 after buying an additional 153 shares during the last quarter. Premier Path Wealth Partners LLC increased its stake in Edwards Lifesciences by 4.4% in the 1st quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company's stock valued at $311,000 after buying an additional 162 shares during the period. Mitchell Sinkler & Starr PA increased its stake in Edwards Lifesciences by 6.4% in the 4th quarter. Mitchell Sinkler & Starr PA now owns 2,900 shares of the medical research company's stock valued at $247,000 after buying an additional 175 shares during the period. Finally, Claret Asset Management Corp raised its position in Edwards Lifesciences by 6.1% during the 4th quarter. Claret Asset Management Corp now owns 3,148 shares of the medical research company's stock worth $268,000 after buying an additional 181 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.5%

EW opened at $88.81 on Wednesday. The business's fifty day moving average is $88.47 and its two-hundred day moving average is $85.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a market cap of $51.14 billion, a price-to-earnings ratio of 51.04, a PEG ratio of 2.32 and a beta of 0.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business's revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter last year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the company's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel Lippis sold 619 shares of the firm's stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $87.51, for a total transaction of $54,168.69. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,503,375.34. This represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 5,664 shares of company stock worth $511,918. 0.31% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

EW has been the subject of several recent analyst reports. Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. UBS Group began coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price target for the company. TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Finally, Citigroup lifted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.